Literature DB >> 21927925

High frequency of vertebral fractures in early spondylarthropathies.

M A C van der Weijden1, I E van der Horst-Bruinsma, J C van Denderen, B A C Dijkmans, M W Heymans, W F Lems.   

Abstract

UNLABELLED: We demonstrated that vertebral fractures (VF) are commonly found in early SpA. Patients with VF had lower lumbar BMD than patients without VF. VF remained frequently 'unrecognized' and untreated. VF have been associated with more back pain, reduced Qol, and increased risk of future fractures which stresses the importance of recognition also in early stage SpA.
INTRODUCTION: VF are a common complication of long-standing ankylosing spondylitis (AS). However, data of VF in early AS patients and in other spondylarthropathies (SpA) are scarce. Therefore we examined the prevalence of VF in early SpA patients and investigated the associations between VF and demographic and disease-related variables.
METHODS: SpA patients were included consecutively and radiographs of the spine were made. VF were assessed according to the method of Genant et al.: fractures were defined as reduction of ≥20% of the vertebrae. Descriptive statistics, t-tests and logistic regression analyses were used to study the relationship between VF and demographic and disease-related variables, radiographic damage and BMD.
RESULTS: A total of 113 early SpA patients were included with a disease duration of 7 months, a mean age of 37 years. Seventeen patients (15%) had at least one VF. Fourteen patients had one VF, three patients had two VF. Most VF were located at Th6-Th8. In patients with VF, bone mineral density (BMD) of lumbar spine was lower than BMD of patients without VF (t-test: p = 0.043). Axial Psoriatic Arthritis (PsA) was significantly associated with a higher risk for VF (odds ratio [OR]: 4.62, 95% confidence interval [CI] 1.15-18.58, p = 0.031). No significant associations were found with disease activity variables nor with radiographic severity.
CONCLUSION: In a group of 113 early, young SpA patients, 15% already had at least one VF. Most VF were asymptomatic, undetected by routine diagnostic procedures and located at the mid-thoracic spine. The VF were associated with low BMD of the lumbar spine and with axial PsA.

Entities:  

Mesh:

Year:  2011        PMID: 21927925     DOI: 10.1007/s00198-011-1766-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  41 in total

Review 1.  The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis.

Authors:  A M Briggs; A M Greig; J D Wark
Journal:  Osteoporos Int       Date:  2007-01-06       Impact factor: 4.507

2.  Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis.

Authors:  Nuria Montala; Xavier Juanola; Eduardo Collantes; Elisa Muñoz-Gomariz; Carlos Gonzalez; Jordi Gratacos; Pedro Zarco; Jose Luis Fernandez Sueiro; Juan Mulero; Juan Carlos Torre-Alonso; Enrique Batlle; Loreto Carmona
Journal:  J Rheumatol       Date:  2011-03-01       Impact factor: 4.666

3.  Bone mineral density in patients with psoriatic arthritis.

Authors:  B Frediani; A Allegri; P Falsetti; L Storri; S Bisogno; F Baldi; P Filipponi; R Marcolongo
Journal:  J Rheumatol       Date:  2001-01       Impact factor: 4.666

4.  Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis.

Authors:  B J Harrison; C E Hutchinson; J Adams; I N Bruce; A L Herrick
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

5.  Bone mineral density and bone turnover in patients with psoriatic arthritis.

Authors:  Pinar Borman; Seçil Babaoğlu; Guneş Gur; Sezin Bingol; Hatice Bodur
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

6.  The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population.

Authors:  M Naves; J B Díaz-López; C Gómez; A Rodríguez-Rebollar; M Rodríguez-García; J B Cannata-Andía
Journal:  Osteoporos Int       Date:  2003-04-25       Impact factor: 4.507

7.  Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study.

Authors:  R Hasserius; M K Karlsson; B E Nilsson; I Redlund-Johnell; O Johnell
Journal:  Osteoporos Int       Date:  2003-01       Impact factor: 4.507

8.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Authors:  M Dougados; S van der Linden; R Juhlin; B Huitfeldt; B Amor; A Calin; A Cats; B Dijkmans; I Olivieri; G Pasero
Journal:  Arthritis Rheum       Date:  1991-10

9.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

10.  The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study.

Authors:  A Papaioannou; C C Kennedy; G Ioannidis; Y Gao; A M Sawka; D Goltzman; A Tenenhouse; L Pickard; W P Olszynski; K S Davison; S Kaiser; R G Josse; N Kreiger; D A Hanley; J C Prior; J P Brown; T Anastassiades; J D Adachi
Journal:  Osteoporos Int       Date:  2007-10-09       Impact factor: 4.507

View more
  26 in total

1.  Density, structure, and strength of the distal radius in patients with psoriatic arthritis: the role of inflammation and cardiovascular risk factors.

Authors:  T Y Zhu; J F Griffith; L Qin; V W Y Hung; T-N Fong; S-K Au; A W Kwok; P-C Leung; E K Li; L-S Tam
Journal:  Osteoporos Int       Date:  2014-08-27       Impact factor: 4.507

Review 2.  [Rheumatism and bone metabolism].

Authors:  G Dischereit; U Lange
Journal:  Orthopade       Date:  2019-11       Impact factor: 1.087

3.  Dissecting the relationship between high-sensitivity serum C-reactive protein and increased fracture risk: the Rotterdam Study.

Authors:  L Oei; N Campos-Obando; A Dehghan; E H G Oei; L Stolk; J B J van Meurs; A Hofman; A G Uitterlinden; O H Franco; M C Zillikens; F Rivadeneira
Journal:  Osteoporos Int       Date:  2013-12-13       Impact factor: 4.507

Review 4.  Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.

Authors:  Cecilia Mercieca; Irene E van der Horst-Bruinsma; Andrew A Borg
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

5.  Bone mass in axial spondyloarthritis: A literature review.

Authors:  Erkan Kilic; Salih Ozgocmen
Journal:  World J Orthop       Date:  2015-03-18

6.  Management and evaluation of extra-articular manifestations in spondyloarthritis.

Authors:  Irene E van der Horst-Bruinsma; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-12       Impact factor: 5.346

Review 7.  C-reactive protein and risk of fracture: a systematic review and dose-response meta-analysis of prospective cohort studies.

Authors:  Z-J Wu; J-L He; R-Q Wei; B Liu; X Lin; J Guan; Y-B Lan
Journal:  Osteoporos Int       Date:  2014-08-09       Impact factor: 4.507

Review 8.  Role of comorbidities in spondyloarthritis including psoriatic arthritis.

Authors:  Silvia Scriffignano; Fabio Massimo Perrotta; Antonia De Socio; Ennio Lubrano
Journal:  Clin Rheumatol       Date:  2018-10-18       Impact factor: 2.980

9.  Ankylosing spondylitis confers substantially increased risk of clinical spine fractures: a nationwide case-control study.

Authors:  D Prieto-Alhambra; J Muñoz-Ortego; F De Vries; D Vosse; N K Arden; P Bowness; C Cooper; A Diez-Perez; P Vestergaard
Journal:  Osteoporos Int       Date:  2014-10-24       Impact factor: 4.507

Review 10.  The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders.

Authors:  Eugenia Bertoldo; Giovanni Adami; Maurizio Rossini; Alessandro Giollo; Giovanni Orsolini; Ombretta Viapiana; Davide Gatti; Angelo Fassio
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.